case_images: PMC11779609_01
case_images: Clinical course and molecular assessment in a 63-year old patient with DDLPS. (A) Graphical summary of the patient history. Over the course of 112 months, the patient underwent a total of seven surgical procedures. Trabectedin therapy, followed by nivolumab treatment, was initiated as a palliative measure at month 43. This approach, combined with a minor tumor resection via jejuno-jejunostomy, resulted in an R0 resection, representing the first successful R0 status achieved 60 months after the initial diagnosis. The patient has since remained without evidence of disease. (B) IHC staining for MLH1 (left, 100x) and CD4, CD5 and CD8 (right, 40x) in representative specimens before and after treatment with trabectedin and nivolumab. Rx, radiation therapy; Ifo-Doxo, ifosfamide-doxorubicin; Tox, hematotoxicity; R0/R1/R2, surgery performed resulting in R0/R1/R2 resection status; HIPEC, intraperitoneal hyperthermic chemoperfusion; Nivo, nivolumab; Trab, trabectedin; CR, complete remission; PEG, percutaneous endoscopic gastrostomy.
case_images: fonc-14-1518775-g001.jpg
case_images: PMC11779609_01_fonc-14-1518775-g001.jpg
case_images: f1
case_images: We investigated this rationale in a 63-year old male patient diagnosed with DDLPS of the retroperitoneum, who subsequently underwent upfront surgery resulting in an R1 resection ( Figure 1A ).